After World-Leading Vaccine Roll-Out, UK Eyes Booster Phase But Faces Pressure To Help Globe
The UK’s purchase of 60 million extra Pfizer/BioNTech COVID vaccine doses, plus bets on Novavax and Valneva and others gives it a buffer against new variants – so when will it pledge to donate to more needy nations?
You may also be interested in...
Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It's also not clear whether it’s an ominous sign for other industry battles in the US, including the drug pricing debate.
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.